Mechanisms of Ischemic Stroke in Cancer Patients
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Cancer, Neurology |
| Therapuetic Areas: | Neurology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/9/2019 |
| Start Date: | November 2015 |
| End Date: | March 2020 |
| Contact: | Babak Navi, MD, MS |
| Phone: | 212-746-0225 |
The purpose of this study is to better understand the causes of stroke in people with cancer.
Active cancer increases the risk of stroke. The investigators do not know exactly why this
occurs but one possible reason is that people with cancer may have thicker blood than people
without cancer. Thick blood can sometimes cause blood clots to form in the heart, which can
then travel to the brain and cause stroke. This study is being done to help figure out why
this and other causes of stroke occur in people with cancer. The investigators expect that
information from this study will help doctors to more effectively prevent and treat stroke in
individuals with cancer.
Active cancer increases the risk of stroke. The investigators do not know exactly why this
occurs but one possible reason is that people with cancer may have thicker blood than people
without cancer. Thick blood can sometimes cause blood clots to form in the heart, which can
then travel to the brain and cause stroke. This study is being done to help figure out why
this and other causes of stroke occur in people with cancer. The investigators expect that
information from this study will help doctors to more effectively prevent and treat stroke in
individuals with cancer.
This will be a prospective cross-sectional study to examine the unique mechanisms of ischemic
stroke in cancer patients. Enrollment will occur at the NewYork-Presbyterian Hospital
(NYPH)/Weill Cornell Medical Center (WCMC) and the Memorial Sloan Kettering Cancer Center
(MSKCC). Measurements will occur at the NYPH/WCMC and MSKCC Neurovascular Ultrasound
Laboratories, the MSKCC Central Laboratory, and the Sharp Laboratory at the University of
California, Davis. Three groups of adult patients will be enrolled. Group 1 will consist of
consecutive patients with active solid tumor cancer and acute ischemic stroke. Group 2 will
be patients with acute ischemic stroke and no cancer. Patients in Groups 1 and 2 will be
enrolled at 96 hours +/- 24 hours of stroke onset. Group 3 will include patients with active
solid tumor cancer and no stroke. This group will allow us to confirm that differences
between stroke patients with and without cancer are not simply incidental findings that can
be expected in all cancer patients regardless of thrombotic status. Demographics,
comorbidities, and stroke severity (for Groups 1 and 2 only) will be recorded on admission
using a structured form. Study patients will undergo three facets of testing: 1) Transcranial
Doppler (TCD) microemboli detection; 2) hematological biomarker testing; 3) peripheral blood
leukocyte RNA gene expression analysis.
stroke in cancer patients. Enrollment will occur at the NewYork-Presbyterian Hospital
(NYPH)/Weill Cornell Medical Center (WCMC) and the Memorial Sloan Kettering Cancer Center
(MSKCC). Measurements will occur at the NYPH/WCMC and MSKCC Neurovascular Ultrasound
Laboratories, the MSKCC Central Laboratory, and the Sharp Laboratory at the University of
California, Davis. Three groups of adult patients will be enrolled. Group 1 will consist of
consecutive patients with active solid tumor cancer and acute ischemic stroke. Group 2 will
be patients with acute ischemic stroke and no cancer. Patients in Groups 1 and 2 will be
enrolled at 96 hours +/- 24 hours of stroke onset. Group 3 will include patients with active
solid tumor cancer and no stroke. This group will allow us to confirm that differences
between stroke patients with and without cancer are not simply incidental findings that can
be expected in all cancer patients regardless of thrombotic status. Demographics,
comorbidities, and stroke severity (for Groups 1 and 2 only) will be recorded on admission
using a structured form. Study patients will undergo three facets of testing: 1) Transcranial
Doppler (TCD) microemboli detection; 2) hematological biomarker testing; 3) peripheral blood
leukocyte RNA gene expression analysis.
Inclusion Criteria
- 18 years of age or older
- Active solid tumor cancer (for Groups 1 and 3 only)
- MRI confirmed acute ischemic stroke (for Groups 1 and 2 only)
- Available for blood draw at 96 hours (+/- 24 hours) from last known well time (for
Groups 1 and 2 only) or within 2 weeks of enrollment (for Group 3)
- Available for TCD within 2 weeks of enrollment
Exclusion Criteria
- Primary brain tumor or hematological cancer
- Treatment with intravenous or intraarterial thrombolysis or mechanical embolectomy
- Platelets < 50,000/mm3
- Hemodialysis within 14 days
- Active pregnancy
- Infection within 14 days per Infectious Diseases Society of America (IDSA) criteria
We found this trial at
2
sites
New York, New York 10021
Principal Investigator: Babak Navi, MD, MS
Phone: 212-746-0225
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Phone: 212-639-7997
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials